Polyrizon (Nasdaq: PLRZ) announced the successful completion of a key manufacturing upscaling milestone for its intranasal C&C platform on Dec 2, 2025. The company and its CDMO transitioned PL-14 from small-batch lab production to a larger-scale controlled run that validated key formulation parameters and showed the PL-14 formulation can be reliably produced at increased batch volumes while maintaining quality.
The batch is intended to support clinical trial material (CTM) for a clinical trial expected to commence in 2026 and is described as produced in line with U.S. and European regulatory standards, advancing readiness for clinical and regulatory activities and potential future commercial manufacturing.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.